Clinical Trial

CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma

Name: CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma — clinical trial record (NCT06482684)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CARMAN

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

First-line CAR-T-cell consolidation after an abbreviated induction with 2 cycles of Rituximab and Ibrutinib prior to CAR-T-cell treatment and followed by 6 months of maintenance with Ibrutinib in patients with high risk MCL.

Trial Details

NCT Number	NCT06482684
Lead Sponsor	Christian Schmidt, MD Collaborators: Johannes Gutenberg University Mainz
Conditions	Mantle Cell Lymphoma
Enrollment	150 participants
Start Date	2024-02-15
Primary Completion	2031-06-15 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-07-01